"Inter Pharma" expects to sell 46 million IPOs at the end of October

Mrs. Phisaporn Roekkaram, Managing Director of Advisory Plus Company Limited, a financial advisor to Inter Pharma (IP), revealed that the Securities and Exchange Commission (SEC) has approved the request for approval. The sale of the securities of Inter Pharma (IPO) is completed. By offering 46 million new shares to the public for the first time (IPO), equivalent to 22.33% of the total issued and paid up shares of the company

Currently, Inter Pharma Company has a registered capital of 103 million baht, divided into 206 million ordinary shares with a par value of 0.50 baht per share, with a registered capital of 80 million baht which has been paid up, representing 160 million shares.

Mr. Ratthachai Theeranawat, Co-Chief Executive Officer Investment Banking Division – Capital Market KTB Securities (Thailand), the underwriter and underwriter of the IP shares, said it is expected to open for IPO by the end of October and to trade on the mai. Beginning in November, offering initial public offering information to institutional investors and general investors around the middle of this month.

For Inter Pharma, the company has good business potential and constantly growing incomes. Therefore, confident in this IPO offering, the dividend payment policy is expected to be at least 50% of the net profit after tax.

Inter Pharma is a development business leader. Inventing and selling anti-aging health products and job innovation for people And health products for pets and livestock

Dr. Songsawut Sak Chalathorn, Chief Executive Officer of Inter Pharma, revealed that the company has a vision to be the inventor. Suggesting different health product offerings With efficiency and safety for disease prevention and treatment For money raised from funding To be used as working capital in the company and operations

For the first 6 months of the year 2018, compared to the first 6 months of the year increased by 32.37%. In addition, with the marketing approach Hoping to expand distribution channels to cover both domestic and foreign target groups. For the long-term good business potential and support sustainable growth

"We set a goal for the next 5 years to grow to be a leading company in offering health products and to expand distribution and marketing channels both in Thailand and overseas. Along with creating the INTERPHARMA brand to become more well-known In order to grow to be a leading international company, "Mr. Songwut said

Read assembly

"Inter Pharma" is preparing to sell 46 million IPOs to mai this year.